Dr. Silvio Inderbitzin is a member of the Board of Directors and also investor in Cellestia.
Dr. Inderbitzin has held multiple senior positions in the pharmaceutical industry during the last 25 years. With his origin in pharmaceutical manufacturing, he built a corporate-wide GMP quality assurance system and was responsible for product release as a Qualified Person in a medium-sized Swiss pharmaceutical company (Spirig Pharma Ltd.) He was later appointed to the position of Technical Director (COO) and served on the corporate management team, ultimately joining the Board of Directors and becoming co-owner of the privately-held 450-employee company. Prior to the successful sale of the company, he served as CEO and was responsible for the foreign subsidiaries.
Today, he is an active investor, consultant and board member of several life science start-ups and medium sized private companies (Pharma/Cosmetic).
Dr. Inderbitzin studied pharmacy at the University of Berne, holds a Ph.D. in pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.